A Tumor-Activatable DNA Nanoengager That Orchestrates NK Receptor Clustering and Immune Checkpoint Blockage to Enhance Antitumor Cytotoxicity
Journal of the American Chemical Society · 2026
DOI: 10.1021/jacs.6c15706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2026. Verfasst von Wen-Jia Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biosystem and Microanalysis, State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufactur…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Antineoplastic Agents, Immune Checkpoint Inhibitors, DNA. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China (NSFC), Natural Science Foundation of Shanghai.
Abstract (Originalsprache)
Natural killer cell engagers (NKCEs) are promising immunotherapeutic agents for cancer treatment. However, their efficacy against solid tumors is severely limited by immune evasion mechanisms (mediated by the sialic acid–Siglec axis and PD-1/PD-L1 pathway), along with poor pharmacokinetics and off-target effects. Harnessing the precision and addressability of DNA origami, we engineered a tissue-specific, DNA origami-based, dual checkpoint-inhibiting NK synapse engager. This nanoplatform adopts a bilayered barrel architecture: the inner layer is functionalized with aNKp46, aPD-L1, and sialidase, while the outer layer is modified with the serum albumin-binding peptide ABD035 and a pH-sensitive i-motif switch. In the acidic tumor microenvironment, the DNA nanoengager undergoes specific dissociation of the outer protective layer, exposing the functional modules. These components concurrently bridge and activate NK cells, block the PD-L1 immune checkpoint, and specifically degrade tumor surface sialic acids, thereby reversing dual immunosuppression. This integrated DNA system enables synergistic integration of targeted activation, dual checkpoint blockade, and tumor microenvironment responsiveness, providing a novel smart nanoscale strategy to overcome multifaceted immune evasion in solid tumors and enhance the safety and efficacy of NK cell-based immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Biosystem and Microanalysis, State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufacturing Technology, East China University of Science and Technology, Shang…
- State Key Laboratory Incubation Base for Green Processing of Chemical Engineering, School of Chemistry and Chemical Engineering, Shihezi University, Shihezi832003, China.
- Shanghai Anshu Bio-tech., Co., Ltd., Shanghai200030, China.
- Department of Pulmonary and Critical Care Medicine, Central Hospital of Fengxian District, Shanghai201400, China.
ORCID-Profile: Bang-Ce Ye
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China (NSFC)
- Natural Science Foundation of Shanghai
Zitieren
APA
Shi, W. J., Li, C. Q., Lai, W. R., Li, X. M., Cheng, H. J., Wang, Y., Gao, Y., Ma, P. Q., & Ye, B. C. (2026). A Tumor-Activatable DNA Nanoengager That Orchestrates NK Receptor Clustering and Immune Checkpoint Blockage to Enhance Antitumor Cytotoxicity. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c15706
Vancouver
Shi WJ, Li CQ, Lai WR, Li XM, Cheng HJ, Wang Y, et al. A Tumor-Activatable DNA Nanoengager That Orchestrates NK Receptor Clustering and Immune Checkpoint Blockage to Enhance Antitumor Cytotoxicity. Journal of the American Chemical Society. 2026. doi:10.1021/jacs.6c15706
BibTeX
@article{Shi2026,
author = {Shi, Wen-Jia and Li, Chao-Qiang and Lai, Wen-Rong and Li, Xiao-Mei and Cheng, Hui-Juan and Wang, Yue and Gao, Yang and Ma, Pei-Qiang and Ye, Bang-Ce},
title = {A Tumor-Activatable DNA Nanoengager That Orchestrates NK Receptor Clustering and Immune Checkpoint Blockage to Enhance Antitumor Cytotoxicity},
journal = {Journal of the American Chemical Society},
year = {2026},
doi = {10.1021/jacs.6c15706}
}
EUVIMED